Ethyl Pyruvate Has Anti-Inflammatory and Delayed Myocardial Protective Effects after Regional Ischemia/Reperfusion Injury
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Ethyl pyruvate has anti-inflammatory properties and protects organs from ischemia/reperfusion (I/R)-induced tissue injury. The aim of this study was to determine whether ethyl pyruvate decreases the inflammatory response after regional I/R injury and whether ethyl pyruvate protects against delayed regional I/R injury in an in vivo rat heart model after a 24 hours reperfusion. Materials and Methods: Rats were randomized to receive lactated Ringer’s solution or ethyl pyruvate dissolved in Ringer’s solution, which was given by intraperitoneal injection 1 hour prior to ischemia. Rats were subjected to 30 min of ischemia followed by reperfusion of the left coronary artery territory. After a 2 hours reperfusion, nuclear factor κB, myocardial myeloperoxidase activity, and inflammatory cytokine levels were determined. After the 24 hours reperfusion, the hemodynamic function and myocardial infarct size were evaluated. Results: At 2hours after I/R injury, ethyl pyruvate attenuated I/R-induced nuclear factor κB translocation and reduced myeloperoxidase activity in myocardium. The plasma circulating levels of inflammatory cytokines decreased significantly in the ethyl pyruvate-treated group. At 24 hours after I/R injury, ethyl pyruvate significantly improved cardiac function and reduced infarct size after regional I/R injury. Conclusion: Ethyl pyruvate has the ability to inhibit neutrophil activation,inflammatory cytokine release, and nuclear factor κB translocation. Ethyl pyruvate is associated with a delayed myocardial protective effect after regional I/R injury in an in vivo rat heart model.
Abstract
Purpose: Ethyl pyruvate has anti-inflammatory properties and protects organs from ischemia/reperfusion (I/R)-induced tissue injury. The aim of this study was to determine whether ethyl pyruvate decreases the inflammatory response after regional I/R injury and whether ethyl pyruvate protects against delayed regional I/R injury in an in vivo rat heart model after a 24 hours reperfusion. Materials and Methods: Rats were randomized to receive lactated Ringer’s solution or ethyl pyruvate dissolved in Ringer’s solution, which was given by intraperitoneal injection 1 hour prior to ischemia. Rats were subjected to 30 min of ischemia followed by reperfusion of the left coronary artery territory. After a 2 hours reperfusion, nuclear factor κB, myocardial myeloperoxidase activity, and inflammatory cytokine levels were determined. After the 24 hours reperfusion, the hemodynamic function and myocardial infarct size were evaluated. Results: At 2hours after I/R injury, ethyl pyruvate attenuated I/R-induced nuclear factor κB translocation and reduced myeloperoxidase activity in myocardium. The plasma circulating levels of inflammatory cytokines decreased significantly in the ethyl pyruvate-treated group. At 24 hours after I/R injury, ethyl pyruvate significantly improved cardiac function and reduced infarct size after regional I/R injury. Conclusion: Ethyl pyruvate has the ability to inhibit neutrophil activation,inflammatory cytokine release, and nuclear factor κB translocation. Ethyl pyruvate is associated with a delayed myocardial protective effect after regional I/R injury in an in vivo rat heart model.
참고문헌 (27)
- Mallet RT, "Metabolic cardioprotection by pyruvate: recent progress", Exp Biol Med (Maywood), 230, pp.435~443 (2005)
- Brand KA, "Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species", FASEB J, 11, pp.388~395 (1997)
- Dobsak P, "Antioxidative properties of pyruvate and protection of the ischemic rat heart during cardioplegia", J Cardiovasc Pharmacol, 34, pp.651~659 (1999)
- Yu YM, "Inhibition of the cerebral inchemic injury by ethyl pyruvate with a wide therapeutic window", Stroke, 36, pp.2238~2243 (2005)
- Cicalese L, "Pyruvate prevents ischemia-reperfusion mucosal injury of rat small intestine", Am J Surg, 171, pp.97~100 (1996)
- Sileri P, "Pyruvate inhibits hepatic ischemia-reperfusion injury in rats", Transplantation, 72, pp.27~30 (2001)
- Fink MP, "Ethyl pyruvate", Curr Opin Anaesthesiol, 21, pp.160~167 (2008)
- Taylor MD, "Ethyl pyruvate enhances ATP levels, reduces oxidative stress and preserves cardiac function in a rat model of off-pump coronary bypass", Heart Lung Circ, 14, pp.25~31 (2005)
- Woo YJ, "Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia", J Thorac Cardiovasc Surg, 127, pp.1262~1269 (2004)
- Kim HS, "Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROSdependent STAT signaling in activated microglia", Free Radic Biol Med, 45, pp.950~963 (2008)
- Kim JB, "Anti-inflammatory mechanism is involved in ethyl pyruvate-mediated efficacious neuroprotection in the postischemic brain", Brain Res, 1060, pp.188~192 (2005)
- Yang R, "Ethyl pyruvate ameliorates acute alcohol-induced liver injury and inflammation in mice", J Lab Clin Med, 142, pp.322~331 (2003)
- 신일우, "Propofol has delayed myocardial protective effects after a regional ischemia", reperfusion injury in an in vivo rat heart model, 2010, pp.58(4), 378~382[DOI]
- Jin YC, "Cryptotanshinone, a lipophilic compound of Salvia miltiorrhiza root, inhibits TNF-alpha-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia", reperfusion injury in vivo, 2009, pp.614, 91~97
- Gwechenberger M, "Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions", Circulation, 99, pp.546~551 (1999)
- Ulloa L, "Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation", Proc Natl Acad Sci U S A, 99, pp.12351~12356 (2002)
- Zingarelli B, "Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-kappaB and AP-1 activation and enhances myocardial damage", FASEB J, 16, pp.327~342 (2002)
- Chandrasekar B, "Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium", FEBS Lett, 401, pp.30~34 (1997)
- Barnes PJ, "Nuclear factor-kappaB; a pivotal transcription factor in chronic inflammatory diseases", N Engl J Med, 336, pp.1066~1071 (1997)
- Han Y, "Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65", J Pharmacol Exp Ther, 312, pp.1097~1105 (2005)
- Tsung A, "Ethyl pyruvate ameliorates liver ischemia-reperfusion injury by decreasing hepatic necrosis and apoptosis", Transplantation, 79, pp.196~204 (2005)
- Reade MC, "Bench-to-bedside review: Amelioration of acute renal impairment using ethyl pyruvate", Crit Care, 9, pp.556~560 (2005)
- Hansen PR, "Role of neutrophils in myocardial ischemia and reperfusion", Circulation, 91, pp.1872~1885 (1995)
- Frangogiannis NG, "The inflammatory response in myocardial infarction", Cardiovasc Res, 53, pp.31~47 (2002)
- Goldmann BU, "Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction", Free Radic Biol Med, 47, pp.79~83 (2009)
- Zhao ZQ, "Dynamic progression of contractile and endothelial dysfunction and infarct extension in the late phase of reperfusion", J Surg Res, 94, pp.133~144 (2000)
- Zhao ZQ, "Progressively developed myocardial apoptotic cell death during late phase of reperfusion", Apoptosis, 6, pp.279~290 (2001)